SEC Form SC 13G filed by Kymera Therapeutics Inc.

11/12/24 10:32:13 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $KYMR alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 KYMERA THERAPEUTICS INC COMMON STOCK Cusip #501575104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #501575104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,107,656 Item 6: 0 Item 7: 5,109,141 Item 8: 0 Item 9: 5,109,141 Item 11: 7.933% Item 12: HC Cusip #501575104 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,109,141 Item 8: 0 Item 9: 5,109,141 Item 11: 7.933% Item 12: IN Item 1(a). Name of Issuer: KYMERA THERAPEUTICS INC Item 1(b). Address of Issuer's Principal Executive Offices: 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN, MA 02472 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 501575104 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,109,141 (b) Percent of Class: 7.933% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,109,141 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of KYMERA THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of KYMERA THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of KYMERA THERAPEUTICS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $KYMR alert in real time by email

Recent Analyst Ratings for

$KYMR

Date	Price Target	Rating	Analyst
11/18/2024	$65.00	Overweight	Stephens
9/9/2024	$60.00	Outperform	Leerink Partners
8/26/2024	$65.00	Peer Perform → Outperform	Wolfe Research
4/22/2024	$53.00	Outperform	Oppenheimer
2/15/2024		Peer Perform	Wolfe Research
1/4/2024		Neutral → Overweight	JP Morgan
1/3/2024	$45.00 → $30.00	Buy → Neutral	BofA Securities
12/19/2023	$26.00	Overweight → Equal Weight	Wells Fargo

More analyst ratings

SEC Form SC 13G filed by Kymera Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $KYMR

$KYMR SEC Filings

SEC Form S-3ASR filed by Kymera Therapeutics Inc.

SEC Form 10-Q filed by Kymera Therapeutics Inc.

Kymera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$KYMR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Baker Bros. Advisors Lp bought $46 worth of shares (1 units at $46.41) (SEC Form 4)

Bvf Partners L P/Il bought $5,301,325 worth of shares (414,105 units at $12.80) (SEC Form 4)

$KYMR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Stephens initiated coverage on Kymera Therapeutics with a new price target

Leerink Partners resumed coverage on Kymera Therapeutics with a new price target

Kymera Therapeutics upgraded by Wolfe Research with a new price target

$KYMR Press Releases

Fastest customizable press release news feed in the world

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

$KYMR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Esposito Pamela exercised 13,500 shares at a strike of $23.86 and sold $651,766 worth of shares (13,500 units at $48.28) (SEC Form 4)

Director Albers Jeffrey W. exercised 5,000 shares at a strike of $10.34 and sold $245,508 worth of shares (5,000 units at $49.10) (SEC Form 4)

SEC Form 4 filed by Director Bvf Partners L P/Il

$KYMR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

$KYMR Financials

Live finance-specific insights

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

$KYMR Market Insights

Live Market Insights

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

Oppenheimer Maintains Outperform on Kymera Therapeutics, Maintains $52 Price Target

B. Riley Securities Maintains Neutral on Kymera Therapeutics, Raises Price Target to $36

$KYMR Leadership Updates

Live Leadership Updates

R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

Recent Analyst Ratings for
$KYMR

$KYMR
SEC Filings

$KYMR
Insider Purchases

$KYMR
Analyst Ratings

$KYMR
Press Releases

$KYMR
Insider Trading

$KYMR
Large Ownership Changes

$KYMR
Financials

$KYMR
Market Insights

$KYMR
Leadership Updates